In This Issue
Cancer Discov August 1 2018 8 (8) 899-902; DOI:10.1158/2159-8290.CD-ITI8-8
A patient with metastatic melanoma initially responded after adoptive T-cell transfer, but an inflammation-induced melanoma cell dedifferentiation resulted in loss of the MART1 tumor antigen and tumor relapse.
In a prospective clinical study of 12 patients with synovial sarcoma, adoptive transfer of autologous NY-ESO-1c259 cells resulted in a 50% objective response rate and long-term persistence of a clonally diverse, fully functional NY-ESO-1c259 cells.
Elevation of proinflammatory cytokines and disruption of blood-CSF barrier are associated with CAR T cell-driven neurotoxicity in patients with B-ALL who were treated with CD19 CAR 19-28ζ T cells.
CAR T cells engineered to recognize three independent tumor antigens for activation, costimulation, and cytokine support limit on-target, off-tumor toxicity for enhanced antitumor efficacy and safety.
Deletions of the mono-ADP-ribosylhydrolase gene MACROD2 enhance intestinal tumorigenesis in a haploinsufficient manner by suppressing PARP1 activity, leading to increased sensitivity to DNA damage and driving chromosome instability.
Melanoma tumorigenesis is accelerated by the uptake of long-chain fatty acids from adipocytes via the FATP1 lipid transporter, and this adipocyte-melanoma cell cross-talk may by disrupted by FATP inhibitors.
YAP expression in Treg cells upregulates the activin receptor to enhance SMAD/TGFβ signaling, promote Treg differentiation, and suppress antitumor immunity, suggesting potential immunotherapeutic targets.